Unlock stock picks and a broker-level newsfeed that powers Wall Street.

KOSDAQ - Delayed Quote KRW

JLK, Inc. (322510.KQ)

Compare
6,330.00
+450.00
+(7.65%)
At close: 3:30:30 PM GMT+9
Loading Chart for 322510.KQ
  • Previous Close 5,880.00
  • Open 6,450.00
  • Bid 6,320.00 x --
  • Ask 6,330.00 x --
  • Day's Range 6,190.00 - 6,450.00
  • 52 Week Range 5,800.00 - 15,233.33
  • Volume 57,254
  • Avg. Volume 264,209
  • Market Cap (intraday) 159.496B
  • Beta (5Y Monthly) 1.31
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

JLK, Inc. provides diagnosis support to the patients with it AI-driven solutions in South Korea. The company offers AI medical and AI security solutions. Its AI platform provides the on-site/real-time service that is connected to various systems built in the hospital and enables the professional needs of physicians to diagnose diseases. The company provides medical management, medical treatment, and medical service in brain diseases, such as ischemic stroke, hemorrhagic stroke, brain aneurysm, and Alzheimer's disease; and in lung diseases, coronary artery disease, prostate cancer, and digital pathology. The company was formerly known as JLK INSPECTION Co.,Ltd. JLK, Inc. is headquartered in Cheongju, South Korea.

www.jlkgroup.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 322510.KQ

View More

Performance Overview: 322510.KQ

Trailing total returns as of 4/10/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

322510.KQ
22.33%
KOSPI Composite Index (^KS11)
1.90%

1-Year Return

322510.KQ
28.74%
KOSPI Composite Index (^KS11)
9.61%

3-Year Return

322510.KQ
11.87%
KOSPI Composite Index (^KS11)
9.46%

5-Year Return

322510.KQ
35.89%
KOSPI Composite Index (^KS11)
31.41%

Compare To: 322510.KQ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 322510.KQ

View More

Valuation Measures

Annual
As of 4/9/2025
  • Market Cap

    148.16B

  • Enterprise Value

    122.50B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    88.95

  • Price/Book (mrq)

    3.00

  • Enterprise Value/Revenue

    85.82

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -14.77%

  • Return on Equity (ttm)

    -44.06%

  • Revenue (ttm)

    1.43B

  • Net Income Avi to Common (ttm)

    -13.45B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    47.77B

  • Total Debt/Equity (mrq)

    44.84%

  • Levered Free Cash Flow (ttm)

    -7.83B

Research Analysis: 322510.KQ

View More

Company Insights: 322510.KQ

Research Reports: 322510.KQ

View More

People Also Watch

Waiting for permission
Allow microphone access to enable voice search

Try again.